Hsu W H, Lee P, Betts D M
J Vet Pharmacol Ther. 1981 Jun;4(2):97-101. doi: 10.1111/j.1365-2885.1981.tb00717.x.
Pupillary response to xylazine (10-300 micrograms/kg, i.v.) norepinephrine (1-30 micrograms/kg. i.v.) and atropine (3-100 micrograms/kg, i.v.) were observed in rats anaesthetized with pentobarbital. Xylazine caused a dose-dependent mydriasis which was antagonized by a selective alpha 2-adrenergic blocking agent, yohimbine (2.5 mg/kg, i.v.). was less effective in antagonizing this effect of xylazine. A selective alpha 1-adrenergic blocking agent, prazosin (2.5 mg/kg, i.v.) was ineffective in reducing the xylazine-induced mydriasis. In contrast, both phentolamine and prazosin blocked the pupillary dilation produced by norepinephrine, while yohimbine was much less effective in antagonizing norepinephrine-induced mydriasis. Atropine also induced a dose-dependent mydriasis which was not affected by yohimbine pretreatment. The present study suggests that the mydriatic effect of xylazine in the rat is mediated by an adrenergic mechanism, possibly by stimulating the alpha 2-adrenergic receptors in the iris and CNS.
在用戊巴比妥麻醉的大鼠中观察了对赛拉嗪(10 - 300微克/千克,静脉注射)、去甲肾上腺素(1 - 30微克/千克,静脉注射)和阿托品(3 - 100微克/千克,静脉注射)的瞳孔反应。赛拉嗪引起剂量依赖性散瞳,这可被选择性α2 - 肾上腺素能阻断剂育亨宾(2.5毫克/千克,静脉注射)拮抗,而选择性α1 - 肾上腺素能阻断剂哌唑嗪(2.5毫克/千克,静脉注射)在拮抗赛拉嗪的这种作用方面效果较差。相反,酚妥拉明和哌唑嗪都能阻断去甲肾上腺素引起的瞳孔扩大,而育亨宾在拮抗去甲肾上腺素引起的散瞳方面效果要差得多。阿托品也引起剂量依赖性散瞳,且不受育亨宾预处理的影响。本研究表明,赛拉嗪在大鼠中的散瞳作用是由肾上腺素能机制介导的,可能是通过刺激虹膜和中枢神经系统中的α2 - 肾上腺素能受体。